Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 3 Interventional

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

ClinicalTrials.gov ID: NCT07761117

Public ClinicalTrials.gov record NCT07761117. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Aug 13, 2026, 7:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants With HFpEF and HFmrEF (Elevate-HF)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF), irrespective of T2DM status, and who are on background dapagliflozin in addition to other background standard of care.

Study identification

NCT ID
NCT07761117
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
6,950 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 27, 2026
Primary completion
Sep 2, 2029
Completion
Sep 2, 2029
Last update posted
Aug 11, 2026

2026 – 2029

United States locations

U.S. sites
69
U.S. states
24
U.S. cities
65
Facility City State ZIP Site status
Research Site Fairhope Alabama 36532
Research Site Beverly Hills California 90211
Research Site Huntington Beach California 92647
Research Site Huntington Park California 90255
Research Site Loma Linda California 92350
Research Site Lomita California 90717
Research Site Northridge California 91324
Research Site Tarzana California 91356
Research Site New Haven Connecticut 06519
Research Site Hialeah Florida 33012
Research Site Jacksonville Florida 32209
Research Site Lakeland Florida 33813
Research Site Miami Florida 33125
Research Site Miami Florida 33144
Research Site Atlanta Georgia 30303
Research Site Columbus Georgia 31904
Research Site Tucker Georgia 30084
Research Site Champaign Illinois 61822
Research Site Park Ridge Illinois 60068
Research Site Schaumburg Illinois 60173
Research Site Indianapolis Indiana 46254
Research Site Waterloo Iowa 50701
Research Site Bossier City Louisiana 71111
Research Site Covington Louisiana 70433
Research Site Lafayette Louisiana 70503
Research Site New Orleans Louisiana 70121
Research Site Shreveport Louisiana 71105
Research Site Baltimore Maryland 21229
Research Site Lanham Maryland 20706
Research Site Oxon Hill Maryland 20745
Research Site Boston Massachusetts 02114
Research Site Boston Massachusetts 02118
Research Site New Bedford Massachusetts 02740
Research Site Worcester Massachusetts 01655
Research Site Flint Michigan 48503
Research Site Southfield Michigan 48076
Research Site Kansas City Missouri 64111
Research Site St Louis Missouri 63136
Research Site Millville New Jersey 08332
Research Site Trenton New Jersey 08690
Research Site Buffalo New York 14215
Research Site New York New York 10001
Research Site The Bronx New York 10451
Research Site The Bronx New York 10455
Research Site Chapel Hill North Carolina 27599
Research Site Durham North Carolina 27710
Research Site Greensboro North Carolina 27410
Research Site Statesville North Carolina 28625
Research Site Wilmington North Carolina 28401
Research Site Fargo North Dakota 58104
Research Site Grand Forks North Dakota 58201
Research Site Columbus Ohio 43228
Research Site Dayton Ohio 45435
Research Site Maumee Ohio 43537
Research Site Oklahoma City Oklahoma 73134
Research Site Philadelphia Pennsylvania 19104
Research Site Philadelphia Pennsylvania 19107
Research Site Yardley Pennsylvania 19067
Research Site DeSoto Texas 75115
Research Site El Paso Texas 79905
Research Site Houston Texas 77025
Research Site Humble Texas 77338
Research Site Lancaster Texas 75216
Research Site Plano Texas 75093
Research Site San Antonio Texas 78231
Research Site Victoria Texas 77901
Research Site Burlington Vermont 05401
Research Site Arlington Virginia 22205
Research Site Redmond Washington 98052

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 297 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07761117, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 11, 2026 · Synced Aug 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07761117 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →